Rate control vs rhythm control in patients with nonvalvular persistent atrial fibrillation - The results of the Polish How to Treat Chronic Atrial Fibrillation (HOT CAFE) study

被引:347
作者
Opolski, G [1 ]
Torbicki, A
Kosior, DA
Szulc, M
Wozakowska-Kaplon, B
Kolodziej, P
Achremczyk, P
机构
[1] Med Univ Warsaw, Dept Cardiol, Warsaw, Poland
[2] Med Univ Warsaw, Dept Internal Med & Hypertens, Warsaw, Poland
[3] Natl Inst TB & Pulm Dis, Dept Chest Med, Warsaw, Poland
[4] Municipal Hosp, Dept Cardiol, Kielce, Poland
[5] Municipal Hosp, Dept Cardiol, Siedlce, Poland
[6] Municipal Hosp, Dept Cardiol, Radom, Poland
关键词
antiarrhythmic therapy; atrial fibrillation; electrocardioversion rate control; rhythm control;
D O I
10.1378/chest.126.2.476
中图分类号
R4 [临床医学];
学科分类号
1002 ; 100602 ;
摘要
Study objectives: The relative risks and benefits of strategies of rate control vs rhythm control in patients with atrial fibrillation (AF) remain to be fully explored. Design: The How to Treat Chronic Atrial Fibrillation (HOT CAFE) Polish trial was designed to evaluate in a randomized, multicenter, and prospective manner the feasibility and long-term outcomes of rate control vs rhythm control strategies in patients with persistent AF. Patients: Our study population comprised 205 patients (134 men and 71 women; mean [+/- SD] age, 60.8 +/- 11.2 years) with a mean AF duration of 273.7 +/- 112.4 days. The mean observation period was 1.7 +/- 0.4 years. One hundred one patients were randomly assigned to the rate control group and received rate-slowing therapy guided by repeated 24-h Holter monitoring. Direct current cardioversion and atrioventricular junctional ablation with pacemaker placement were alternative nonpharmacologic strategies for patients with tachycardia that was resistant to medical therapy. One hundred four patients were randomized to sinus rhythm restoration and maintenance using serial cardioversion supported by a predefined stepwise antiarrhythmic drug regimen (ie, disopyramide, propafenone, sotalol, and amiodarone). In both groups, thromboembolic prophylaxis followed current guidelines. Measurements and results: At the end of follow-up, 63.5% of patients in the rhythm control arm remained in sinus rhythm. No significant differences in the composite end point (ie, all-cause mortality, number of thromboembolic events, or major bleeding) were found between the rate control group and the rhythm control group (odds ratio, 1.98; 95% confidence interval, 0.28 to 22.3; p > 0.71). The incidence of hospital admissions was much lower in the rate control arm (12% vs 74%, respectively; p < 0.001). New York Heart Association functional class improved in both study groups, while mean exercise tolerance, as measured by the maximal treadmill workload, improved only in the rhythm control group (5.2 +/- 5.1 vs 7.6 +/- 3.3 metabolic equivalents, respectively; p < 0.001). The rhythm control strategy led to an increased mean left ventricular fractional shortening (29 +/- 7% vs 31 +/- 7%, respectively; p < 0.01). One episode of pulmonary embolism occurred in the rate control group despite oral anticoagulation therapy, while three patients in the rhythm control arm of the study experienced ischemic strokes (not significant). Conclusions: The Polish HOT CAFE study revealed no significant differences in major end points between the rate control group and the rhythm control group.
引用
收藏
页码:476 / 486
页数:11
相关论文
共 19 条
[1]   Randomized trial of rate-control versus rhythm-control in persistent atrial fibrillation - The Strategies of Treatment of Atrial Fibrillation (STAF) study [J].
Carlsson, J ;
Miketic, S ;
Windeler, J ;
Cuneo, A ;
Haun, S ;
Micus, S ;
Walter, S ;
Tebbe, U .
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2003, 41 (10) :1690-1696
[2]   EFFICACY AND SAFETY OF QUINIDINE THERAPY FOR MAINTENANCE OF SINUS RHYTHM AFTER CARDIOVERSION - A METAANALYSIS OF RANDOMIZED CONTROL TRIALS [J].
COPLEN, SE ;
ANTMAN, EM ;
BERLIN, JA ;
HEWITT, P ;
CHALMERS, TC .
CIRCULATION, 1990, 82 (04) :1106-1116
[3]   SERIAL ANTIARRHYTHMIC DRUG-TREATMENT TO MAINTAIN SINUS RHYTHM AFTER ELECTRICAL CARDIOVERSION FOR CHRONIC ATRIAL-FIBRILLATION OR ATRIAL-FLUTTER [J].
CRIJNS, HJ ;
VANGELDER, IC ;
VANGILST, WH ;
HILLEGE, H ;
GOSSELINK, AM ;
LIE, KI .
AMERICAN JOURNAL OF CARDIOLOGY, 1991, 68 (04) :335-341
[4]   GUIDELINES FOR IMPLANTATION OF CARDIAC-PACEMAKERS AND ANTIARRHYTHMIA DEVICES - A REPORT OF THE AMERICAN-COLLEGE-OF-CARDIOLOGY AMERICAN-HEART-ASSOCIATION TASK-FORCE ON ASSESSMENT OF DIAGNOSTIC AND THERAPEUTIC CARDIOVASCULAR PROCEDURES (COMMITTEE ON PACEMAKER IMPLANTATION) [J].
DREIFUS, LS ;
FISCH, C ;
GRIFFIN, JC ;
GILLETTE, PC ;
MASON, JW ;
PARSONNET, V .
CIRCULATION, 1991, 84 (01) :455-467
[5]   ANTIARRHYTHMIC DRUG-THERAPY AND CARDIAC MORTALITY IN ATRIAL-FIBRILLATION [J].
FLAKER, GC ;
BLACKSHEAR, JL ;
MCBRIDE, R ;
KRONMAL, RA ;
HALPERIN, JL ;
HART, RG .
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 1992, 20 (03) :527-532
[6]   Proarrhythmia [J].
Friedman, PL ;
Stevenson, WG .
AMERICAN JOURNAL OF CARDIOLOGY, 1998, 82 (8A) :50N-56N
[7]  
GOSSELINK ATM, 1994, BRIT HEART J, V72, P161
[8]  
GROGAN M, 1992, EUR HEART J, V13, P1290
[9]   Rhythm or rate control in atrial fibrillation - Pharmacological intervention in atrial fibrillation (PIAF): a randomised trial [J].
Hohnloser, SH ;
Kuck, KH ;
Lilienthal, J .
LANCET, 2000, 356 (9244) :1789-1794
[10]   ANTITHROMBOTIC THERAPY IN ATRIAL-FIBRILLATION [J].
LAUPACIS, A ;
ALBERS, G ;
DALEN, J ;
DUNN, M ;
FEINBERG, W ;
JACOBSON, A .
CHEST, 1995, 108 (04) :S352-S359